gene

GRN

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about GRN: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

985Connections

1Hypotheses

1Analyses

50Outgoing

50Incoming

1Experiments

1Debates

Summary

Gene profile: GRN - Progranulin gene in FTD and NCL

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	GRN
Full Name	Progranulin
Aliases	Gene profile: GRN
Chromosome	17q21.31
Protein Family	Granulin family
Function	Each granulin domain is approximately 90 amino acids with 12 conserved cysteine residues forming 6 disulfide bonds, creating a compact, stable structure[3].
Primary Expression	Cerebral cortex, Hippocampus, Microglia, Substantia nigra
Subcellular Localization	Secreted; also localizes to lysosomes
Molecular Weight	~90 kDa (secreted); 68 kDa (granulin domain)
Amino Acids	593 aa
Pathways	Autophagy, Immune Response
UniProt ID	P28799
Ensembl ID	ENSG00000030582
GeneCards	GRN
Human Protein Atlas	GRN
Associated Diseases	Aging, Als, Alzheimer, Alzheimer's disease
Interactions	Actin, AD, ALS, ALZHEIMER, ALZHEIMER DISEASE, ALZHEIMER'S DISEASE
KG Connections	985 knowledge graph edges
Databases	GeneCards NCBI Gene HPA STRING

🔮 Predicted Structure: GRN — AlphaFold P28799 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (11)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    GRN["GRN"]
    GRN -->|"encodes"| progranulin["progranulin"]
    GRN -->|"regulates"| microglia["microglia"]
    GRN -->|"inhibits"| aberrant_microglia_activation["aberrant microglia activation"]
    GRN -->|"causes"| lysosomal_dysfunction["lysosomal dysfunction"]
    GRN -->|"activates"| Alzheimer["Alzheimer"]
    GRN -->|"activates"| Dementia["Dementia"]
    GRN -->|"activates"| Als["Als"]
    GRN -->|"target for"| Amyotrophic_Lateral_Sclerosis["Amyotrophic Lateral Sclerosis"]
    CTSB["CTSB"] -->|"activates"| GRN
    C1QA["C1QA"] -->|"activates"| GRN
    SPP1["SPP1"] -->|"activates"| GRN
    C9ORF72["C9ORF72"] -->|"target for"| GRN
    GENES["GENES"] -->|"target for"| GRN
    DNA["DNA"] -->|"activates"| GRN
    FUS["FUS"] -->|"target for"| GRN
    ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"] -->|"target for"| GRN
    ACE["ACE"] -->|"target for"| GRN

Outgoing (611)

Target	Relation	Type	Str
benchmark_ot_ad_answer_key:GRN	data_in	dataset_row	0.00
ds-83b31ef18d49	provides_data_for	dataset	1.00
Neuronal ceroid lipofuscinosis	causes	disease	0.95
Frontotemporal Dementia	risk_factor_for	disease	0.95
Frontotemporal Lobar Degeneration	risk_factor_for	disease	0.95
Lysosomal Function	involved_in	process	0.95
Astrocyte Toxicity	mediates	mechanism	0.90
microglial inflammatory response	suppresses	process	0.85
Alzheimer Disease	risk_factor_for	disease	0.85
Neuroinflammation	regulates	process	0.85
TAR	interacts_with	gene	0.80
neuronal ceroid lipofuscinosis	causes	disease	0.80
FTLD	implicated_in	disease	0.80
frontotemporal dementia	causes	disease	0.80
Disease Pathogenesis	involved_in	process	0.80
Inflammation	therapeutic_target	disease	0.75
Als	therapeutic_target	disease	0.75
Dementia	therapeutic_target	disease	0.75
Dementia	causes	disease	0.75
Neurodegeneration	therapeutic_target	disease	0.75
Amyotrophic Lateral Sclerosis	therapeutic_target	disease	0.75
RAGE	disrupts	gene	0.70
LEWY BODY DEMENTIA	disrupts	disease	0.70
MACROPHAGE	regulates	cell_type	0.70
MACROPHAGE	causes	cell_type	0.70
MAPT	markers	gene	0.70
MICROGLIA	expresses	cell_type	0.70
TREM2	expresses	gene	0.70
OLIGODENDROCYTE	markers	cell_type	0.70
TREM2	inhibits	gene	0.70
OLIGODENDROCYTES	markers	cell_type	0.70
STING	markers	gene	0.70
VCP	activates	gene	0.70
NEURONS	associated_with	cell_type	0.70
STING	degrades	gene	0.70
SQSTM1	activates	gene	0.70
NEURONS	markers	cell_type	0.70
MAPT	activates	gene	0.70
MICROGLIA	protects_against	cell_type	0.70
microglia	regulates	cell_type	0.70
frontotemporal dementia	associated_with	disease	0.70
aberrant microglia activation	inhibits	process	0.70
Parkinson's disease	causes	disease	0.70
lysosomal dysfunction	causes	process	0.70
RNA	associated_with	gene	0.70
ubiquitin-proteasome	participates_in	pathway	0.70
autophagy pathway	participates_in	pathway	0.70
neurodegeneration	interacts_with	disease	0.70
frontotemporal lobar degeneration	associated_with	disease	0.70
neurodegeneration	regulates	disease	0.70

Incoming (374)

Source	Relation	Type	Str
benchmark_ot_ad_answer_key:GRN	data_in	dataset_row	0.00
ds-83b31ef18d49	data_in	dataset	1.00
SPP1	upregulates	gene	0.90
ALZHEIMER DISEASE	associated_with	gene	0.80
DNA	interacts_with	gene	0.80
GPNMB	associated_with	gene	0.80
APOE	expresses	gene	0.70
AMPK	activates	gene	0.70
AMYOTROPHIC LATERAL SCLEROSIS	associated_with	disease	0.70
APOE	protects_against	gene	0.70
C9ORF72	markers	gene	0.70
FRONTOTEMPORAL DEMENTIA	associated_with	disease	0.70
BIN1	interacts_with	gene	0.70
BIN1	targets	gene	0.70
CD2AP	causes	gene	0.70
APOE	causes	gene	0.70
FTD	protects_against	disease	0.70
C9ORF72	interacts_with	gene	0.70
FTD	regulates	disease	0.70
NEURODEGENERATION	therapeutic_target	gene	0.70
NEURODEGENERATIVE DISEASES	therapeutic_target	gene	0.70
GENES	therapeutic_target	gene	0.70
FTLD	regulates	gene	0.70
DEMENTIA	interacts_with	disease	0.65
CORTEX	treats	brain_region	0.65
LYSOSOMAL DYSFUNCTION	treats	phenotype	0.65
NEURONS	activates	cell_type	0.65
NEURON	treats	cell_type	0.65
FRONTOTEMPORAL DEMENTIA	causes	disease	0.65
TREM2	treats	gene	0.65
ASTROCYTE	associated_with	gene	0.65
TMEM106B	increases_risk	gene	0.65
TMEM106B	causes	gene	0.65
CLU	associated_with	gene	0.65
FUS	co_discussed	gene	0.65
TREM2	interacts_with	gene	0.65
FUS	causes	gene	0.60
C9ORF72	causes	gene	0.60
BIN1	associated_with	entity	0.60
C9ORF72	protects_against	gene	0.60
MAPT	associated_with	gene	0.60
FUS	therapeutic_target	gene	0.60
CD2AP	associated_with	entity	0.60
TAU	therapeutic_target	gene	0.60
IDUA	therapeutic_target	gene	0.60
SPP1	activates	gene	0.60
ATP13A2	regulates	gene	0.60
PILRA	therapeutic_target	gene	0.60
GAIN	associated_with	gene	0.60
GBA	regulates	gene	0.60

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Astrocyte-Neuron Metabolic Coupling Failure Precedes Neurode	0.690	neurodegeneration	Gap 006 analysis (archived stub)

Mentioning Analyses (1)

Scientific analyses that reference this entity

Cell type vulnerability in Alzheimer's Disease (SEA-AD data - v2)

neurodegeneration | 2026-04-03 | 7 hypotheses Top: 0.726

Experiments (1)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Presymptomatic GRN Carrier Intervention Timing — Biomarker-Guided Ther	clinical	Neurodegeneration	0.400	0.50	human	proposed	$5,460,000

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (1)

Multi-agent debates referencing this entity

What cell types are most vulnerable in Alzheimer's Disease based on SEA-AD trans

closed · Rounds: 4 · Score: 0.95 · 2026-04-03

GRN

Understanding Entity Pages

Summary

Wiki Pages (11)

GRN — Progranulin

GRN Progranulin FTD Causal Chain

Progranulin Protein (PGRN)

Progranulin (PGRN)

Progranulin (PGRN) - Biomarker

GRN Carrier Resilience in Frontotemporal Dementia

GRN Carrier Resilience: Why Some Mutation Carriers Remain Asymptomatic

TDP-43 vs Tau Pathology Determination in GRN vs MAPT Mutation Carriers

Presymptomatic GRN Carrier Intervention Timing — Biomarker-Guided Therapy Initiation

GRN (Redirect)

GRN-Mutant Neurons